15 Top Performing European Stocks So Far in 2023
The Bank of England on March 23 raised its benchmark lending rate by a quarter point to 4.25%, the highest since 2008.
Nucana Plc (NCNA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 45,072 | $53,635 | 0% | |
| 2. | Citadel Investment Group Ken Griffin | 25,003 | $29,754 | 0% | |
| 3. | Renaissance Technologies Jim Simons | 0 | $0 | -100% | 0% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 133,333 | $158,666 | 0% | |
| 2. | 46,722 | $55,599 | 0% | |
| 3. | 36,704 | $43,678 | 0% | |
| 4. | 20,986 | $24,973 | 0% | |
| 5. | 17,715 | $21,081 | 0% |
News See All
5 Best Biotech Penny Stocks To Buy Now
NuCana plc (NASDAQ:NCNA) is a British biotech firm which develops drug therapies to treat various forms of cancer.
5 Best Biotech Stocks Under $5
NuCana plc (NASDAQ:NCNA) is a UK-based biotech company focused on discovering treatments for different types of cancer.
Is NCNA A Good Stock To Buy Now?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.
NuCana plc (NCNA): Are Hedge Funds Right About This Stock?
Is NuCana plc (NASDAQ:NCNA) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock.
Billionaire Hedge Funds
